Thermo Fisher CEO Casper sells $8.6m in stock, exercises options By Investing.com

Marc N. Casper, Chairman and CEO of Thermo Fisher Scientific Inc. (), sold common stock totaling $8,628,433 and exercised stock options on August 5, 2026. The transactions were conducted under a Rule 10b5-1 trading plan adopted on April 27, 2026. The stock currently trades at $588.29, up over 20% in the past year.

Mr. Casper disposed of a total of 15,000 shares of common stock, with prices ranging from $566.25 to $577.56 per share. Of these, 10,000 shares were sold directly, and an additional 5,000 shares were sold indirectly through Floral Park Associates, Inc.

On the same day, Mr. Casper acquired 10,000 shares of Thermo Fisher Scientific common stock by exercising stock options at a price of $309.63 per share, amounting to a total value of $3,096,300. The options had vested in four equal installments between February 25, 2021, and February 25, 2024. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, though the company has delivered strong returns. Investors can access detailed analysis through comprehensive Pro Research Reports, available for TMO and 1,400+ other US stocks.

Following these transactions, Mr. Casper directly holds 123,925.358 shares of common stock and indirectly holds 9,608 shares through Floral Park Associates, Inc. He also holds 30,550 derivative stock options.

In other recent news, Thermo Fisher Scientific reported its second-quarter 2026 financial results, surpassing Wall Street expectations. The company posted adjusted earnings of $6.03 per share on revenue of $11.99 billion, exceeding analyst estimates of $5.72 per share and $11.71 billion in sales. This performance represents a 10% increase in revenue compared to the previous year, with organic revenue growth at 5%. Following a stronger-than-expected first half, Thermo Fisher raised its full-year outlook for both revenue and adjusted earnings per share. The company noted improved customer activity across its end markets, particularly in the pharma and biotech sectors, as well as in academic and government markets. Additionally, Thermo Fisher’s adjusted operating margin increased to 22.8% from 21.9% a year earlier. The company attributed part of its revenue growth to recent acquisitions, which contributed significantly to its overall performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.